Time course of serum testosterone and luteinizing hormone levels after cessation of long‐term luteinizing hormone‐releasing hormone agonist treatment in patients with prostate cancer

Kaku, Haruki; Sakaguchi, Takashi; Tsushima, Tomoyasu; Ebara, Shin; Senoh, Takashi; Yamato, Toyoko; Nasu, Yasutomo; Kumon, Hiromi

doi:10.1002/pros.20341

Cited by 79 publications

(64 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[3][4][5][6][7]9,21,22 Therefore, it is not surprising that a correlation between patient baseline testosterone level and timing of testosterone normalization was found in this study. We failed to demonstrate a correlation between age and timing of testosterone normalization in our patients.…”

Section: Discussionsupporting

confidence: 56%

“…However, when it comes to long-term ADT, things become complicated. In a study which included 32 patients who received ADT for a minimum of 2 years (24-87 months) as an adjuvant therapy for RP or external beam radiation therapy (EBRT), Kaku et al 7 revealed that it took 30 months for more than 90% patients to recover to supracastrate testosterone level. Yoon et al 4 also reported that after 2 years of adjuvant ADT for PCa patients underwent RP, it took 36 months for 93.2% patients to recover to supracastrate testosterone level.…”

Section: Discussionmentioning

confidence: 99%

“…[3][4][5][6][7][8][9] It has been reported that if a patient had baseline testosterone level below the normal range, it is difficult for him to recover to normal range after the cessation of ADT. 4 The first strength of the present study is that we defined a serum testosterone level o230 ng dl 21 as normal and excluded patients whose baseline testosterone lower than normal level.…”

Section: Discussionmentioning

confidence: 99%

“…Most previous studies which investigated testosterone recovery included patients treated by ADT combined with EBRT and did not set a control group receiving EBRT alone. [3][4][5][6][7][8][9] Therefore, they could not separate the effects of ADT on the extent and timing of testosterone recovery from that of EBRT plus ADT. [3][4][5][6][7][8][9] Benefit from the design of this study, testosterone recovery in our patients bears only the effect of 9-month adjuvant ADT.…”

Section: Discussionmentioning

confidence: 99%

“…Most previous studies investigating this issue are retrospectively designed and have some limitations, including (i) devoid of measuring baseline testosterone level before ADT; (ii) inconsistency of ADT duration in the same study; and (iii) lack of considering the effect of radiation therapy on testosterone recovery. [3][4][5][6][7][8][9][10] Therefore, the results from previous studies are controversial and confusing.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Kinetics of testosterone recovery in clinically localized prostate cancer patients treated with radical prostatectomy and subsequent short-term adjuvant androgen deprivation therapy

Dai¹,

Qu²,

Kong³

et al. 2013

Asian J Androl

View full text Add to dashboard Cite

Androgen deprivation therapy (ADT) is a standard treatment for metastatic, recurrent and locally advanced prostate cancer (PCa). The aim of this study is to investigate the timing and extent of testosterone recovery in clinically localized PCa patients treated with radical prostatectomy (RP) and subsequent short-term adjuvant ADT. A total of 95 localized PCa patients underwent RP and 9-month adjuvant ADT were included in this prospective study. Serum testosterone level was measured before adjuvant ADT, at ADT cessation, and at 1, 3, 6, 9 and 12 months after cessation of ADT. A Cox proportional hazards model was used to assess variables associated with the time of testosterone normalization. The results showed that median patient age was 67 years and median testosterone level before adjuvant ADT was 361 (230-905) ng dl 21 . All patients finished 9-month adjuvant ADT and achieved castrate testosterone level. At 3 months after ADT cessation, testosterone recovered to supracastrate level in 97.9% patients and to normal level in 36.9% patients. The percentage of patients who recovered to normal testosterone level increased to 66.3%, 86.3% and 92.6% at 6, 9 and 12 months, respectively. Cox regression model found that higher baseline testosterone level (o300 ng dl 21 ) was the only variable associated with a shorter time to testosterone normalization (hazard ratio: 1.98; P 5 0.012). In conclusion, in most patients, testosterone recovered to supracastrate level at 3 months and to normal level at 12 months after 9-month adjuvant ADT cessation. Patients with higher baseline testosterone level need shorter time of testosterone normalization.

show abstract